Literature DB >> 31462561

Interference with SAMHD1 Restores Late Gene Expression of Modified Vaccinia Virus Ankara in Human Dendritic Cells and Abrogates Type I Interferon Expression.

Katja Sliva1, Judith Martin1, Christine von Rhein1, Tobias Herrmann1, Anastasia Weyrich1, Masako Toda2,3, Barbara S Schnierle4.   

Abstract

Attenuated poxviruses like modified vaccinia virus Ankara (MVA) are promising vectors for vaccines against infectious diseases and cancer. However, host innate immune responses interfere with the viral life cycle and also influence the immunogenicity of vaccine vectors. Sterile alpha motif (SAM) domain and histidine-aspartate (HD) domain-containing protein 1 (SAMHD1) is a phosphohydrolase and reduces cellular deoxynucleoside triphosphate (dNTP) concentrations, which impairs poxviral DNA replication in human dendritic cells (DCs). Human immunodeficiency virus type 2 (HIV-2) and simian immunodeficiency virus (SIV) encode an accessory protein called viral protein X (Vpx) that promotes proteasomal degradation of SAMHD1, leading to a rapid increase in cellular dNTP concentrations. To study the function of SAMHD1 during MVA infection of human DCs, the SIV vpx gene was introduced into the MVA genome (resulting in recombinant MVA-vpx). Infection of human DCs with MVA-vpx led to SAMHD1 protein degradation and enabled MVA-vpx to replicate its DNA genome and to express genes controlled by late promoters. Late gene expression by MVA-vpx might improve its vaccine vector properties; however, type I interferon expression was unexpectedly blocked by Vpx-expressing MVA. MVA-vpx can be used as a tool to study poxvirus-host interactions and vector safety.IMPORTANCE SAMHD1 is a phosphohydrolase and reduces cellular dNTP concentrations, which impairs poxviral DNA replication. The simian SIV accessory protein Vpx promotes degradation of SAMHD1, leading to increased cellular dNTP concentrations. Vpx addition enables poxviral DNA replication in human dendritic cells (DCs), as well as the expression of viral late proteins, which is normally blocked. SAMHD1 function during modified vaccinia virus Ankara (MVA) infection of human DCs was studied with recombinant MVA-vpx expressing Vpx. Infection of human DCs with MVA-vpx decreased SAMHD1 protein amounts, enabling MVA DNA replication and expression of late viral genes. Unexpectedly, type I interferon expression was blocked after MVA-vpx infection. MVA-vpx might be a good tool to study SAMHD1 depletion during poxviral infections and to provide insights into poxvirus-host interactions.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  MVA; SAMHD1; dendritic cells; vaccinia virus; vpxzzm321990

Year:  2019        PMID: 31462561      PMCID: PMC6819912          DOI: 10.1128/JVI.01097-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  HIV-1 and HIV-2 differentially mature plasmacytoid dendritic cells into IFN-producing cells or APCs.

Authors:  Caroline M Royle; David R Graham; Simone Sharma; Dietmar Fuchs; Adriano Boasso
Journal:  J Immunol       Date:  2014-08-25       Impact factor: 5.422

2.  Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes.

Authors:  R Drillien; D Spehner; A Bohbot; D Hanau
Journal:  Virology       Date:  2000-03-15       Impact factor: 3.616

Review 3.  Vaccinia virus evasion of regulated cell death.

Authors:  David L Veyer; Guia Carrara; Carlos Maluquer de Motes; Geoffrey L Smith
Journal:  Immunol Lett       Date:  2017-03-31       Impact factor: 3.685

4.  Poxviruses Evade Cytosolic Sensing through Disruption of an mTORC1-mTORC2 Regulatory Circuit.

Authors:  Nathan Meade; Colleen Furey; Hua Li; Rita Verma; Qingqing Chai; Madeline G Rollins; Stephen DiGiuseppe; Mojgan H Naghavi; Derek Walsh
Journal:  Cell       Date:  2018-08-02       Impact factor: 41.582

5.  Nonreplicating vaccinia vector efficiently expresses recombinant genes.

Authors:  G Sutter; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

6.  Differential induction of apoptosis, interferon signaling, and phagocytosis in macrophages infected with a panel of attenuated and nonattenuated poxviruses.

Authors:  Sandra Royo; Bruno Sainz; Enrique Hernández-Jiménez; Hugh Reyburn; Eduardo López-Collazo; Susana Guerra
Journal:  J Virol       Date:  2014-03-05       Impact factor: 5.103

7.  HIV-2 Vpx protein interacts with interferon regulatory factor 5 (IRF5) and inhibits its function.

Authors:  Xiaogang Cheng; Lee Ratner
Journal:  J Biol Chem       Date:  2014-02-14       Impact factor: 5.157

8.  Host factor SAMHD1 restricts DNA viruses in non-dividing myeloid cells.

Authors:  Joseph A Hollenbaugh; Peter Gee; Jonathon Baker; Michele B Daly; Sarah M Amie; Jessica Tate; Natsumi Kasai; Yuka Kanemura; Dong-Hyun Kim; Brian M Ward; Yoshio Koyanagi; Baek Kim
Journal:  PLoS Pathog       Date:  2013-06-27       Impact factor: 6.823

9.  A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses.

Authors:  Sonia T Wennier; Kay Brinkmann; Charlotte Steinhäußer; Nicole Mayländer; Claudia Mnich; Ursula Wielert; Ulrike Dirmeier; Jürgen Hausmann; Paul Chaplin; Robin Steigerwald
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

10.  SAMHD1-dependent retroviral control and escape in mice.

Authors:  Jan Rehwinkel; Jonathan Maelfait; Anne Bridgeman; Rachel Rigby; Bruce Hayward; Rachel A Liberatore; Paul D Bieniasz; Greg J Towers; Luis F Moita; Yanick J Crow; David T Bonthron; Caetano Reis e Sousa
Journal:  EMBO J       Date:  2013-07-19       Impact factor: 11.598

View more
  2 in total

Review 1.  Retroviral Restriction Factors and Their Viral Targets: Restriction Strategies and Evolutionary Adaptations.

Authors:  Guney Boso; Christine A Kozak
Journal:  Microorganisms       Date:  2020-12-11

2.  Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors.

Authors:  Shirley Tenesaca; Marcos Vasquez; Maite Alvarez; Itziar Otano; Myriam Fernandez-Sendin; Claudia Augusta Di Trani; Nuria Ardaiz; Celia Gomar; Angela Bella; Fernando Aranda; José Medina-Echeverz; Ignacio Melero; Pedro Berraondo
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.